| Code | CSB-RA013481MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Etalanetug, designed for research targeting microtubule-associated protein tau (MAPT). MAPT plays a crucial role in stabilizing microtubules in neurons and maintaining axonal transport. Under pathological conditions, MAPT undergoes abnormal hyperphosphorylation and aggregation, forming neurofibrillary tangles that are hallmark features of Alzheimer's disease and other tauopathies, including frontotemporal dementia, progressive supranuclear palsy, and chronic traumatic encephalopathy. These tau aggregates disrupt neuronal function and contribute to neurodegeneration.
Etalanetug is an investigational humanized monoclonal antibody that specifically targets the mid-region of tau protein, designed to bind extracellular tau and prevent its cell-to-cell propagation. This biosimilar antibody serves as a valuable tool for investigating tau pathology mechanisms, studying protein-protein interactions involving MAPT, and exploring therapeutic strategies for neurodegenerative diseases. It enables researchers to examine tau spreading, aggregation dynamics, and potential intervention points in tauopathy disease models.
There are currently no reviews for this product.